Agilent snaps up pathology firm Biocare Medical for $950 million

Anabelle Colaco
11 Mar 2026, 01:12 GMT+10

Agilent Technologies said it will acquire privately held clinical pathology company Biocare Medical in an all-cash deal valued at US$950 million
The life sciences firm said it will purchase the California-based company from private equity owners Excellere Partners and GHO Capital Partners
Following completion of the deal, Biocare Medical will be integrated into Agilent’s Life Sciences and Diagnostics Markets unit

SANTA CLARA, California: Agilent Technologies said it will acquire privately held clinical pathology company Biocare Medical in an all-cash deal valued at US$950 million.

The life sciences firm said it will purchase the California-based company from private equity owners Excellere Partners and GHO Capital Partners. The transaction is expected to close by the fourth fiscal quarter of 2026.

Following completion of the deal, Biocare Medical will be integrated into Agilent's Life Sciences and Diagnostics Markets unit.

Biocare Medical develops integrated tissue diagnostic products used in detecting cancer and infectious diseases. According to its website, its customers include government and military laboratories.

Agilent, which has a market capitalization of about $33.38 billion based on LSEG data, reported first-quarter results in February that were broadly in line with analysts' expectations, indicating steady demand for its medical tools and laboratory equipment.

Watch latest videos

News RELEASES

Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Tuscaloosa Times.

More Information